STAT

JANUARY 8, 2024

Turn on your TV or open a web browser this January, and you’ll be bombarded with ads for fitness trackers, smart scales, health apps, and other digital innovations promising to streamline your journey to a happier and healthier you. It’s the time of year when we’re most susceptible to such messaging: Surveys show that at least one-third of our New Year’s resolutions focus on exercising, losing weight, or eating better.

357

357

PharmaVoice

JANUARY 8, 2024

New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.

190

190

STAT

JANUARY 8, 2024

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years. That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech.

323

323

ALiEM - Pharm Pearls

JANUARY 8, 2024

A 49-year-old female with a past medical history of recurrent diverticulitis initially presented with one month of shortness of breath and a minor nonproductive cough for which she was started on doxycycline by her primary care provider. She then developed a rash on her chest, upper back, and face. Antibiotics were switched to amoxicillin and azithromycin.

Hospitals 150

Hospitals 150

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JANUARY 8, 2024

Medicare Advantage members continue to go to the doctor and get health care procedures a lot more than predicted, CVS Health executives said at the J.P. Morgan Healthcare Conference on Monday. A persistent theme for health insurance companies throughout 2023 has been their Medicare Advantage members using more care than their actuaries projected, which has been eating into the profits they get from federally funded health care premiums.

Health Insurance Companies 320

Health Insurance Companies 320

PharmaVoice

JANUARY 8, 2024

Small and mid-sized drugmakers shed at least 10,000 jobs in 2023, according to data compiled by BioPharma Dive, but recent deal, stock market momentum have brought some optimism.

130

130

pharmaphorum

JANUARY 8, 2024

Dr Peter Marks, director of the FDA Center for Biologics Evaluation and Research told a packed house in San Francisco for JPM that FDA wants to support gene therapies in 2024.

134

134

STAT

JANUARY 8, 2024

SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday. The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P.

Mayo Clinic 309

Mayo Clinic 309

PharmExec

JANUARY 8, 2024

Huestis discusses the ways that quantum simulation and quantum systems can be used in areas such as drug discovery and the creation and protection of intellectual property in the life sciences industry.

126

126

STAT

JANUARY 8, 2024

SAN FRANCISCO — If you learned anything about nonprofit hospitals on the first day of the J.P. Morgan Healthcare Conference, it’s that they’ve all but abandoned the prospect of making significant profit on patient care. Instead, they’re fully throwing their weight into other ways of making money — things like developing drugs or selling insurance.

Hospitals 300

Hospitals 300

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

PharmaVoice

JANUARY 8, 2024

J&J is leading a grassroots effort to improve mental health access and care.

130

130

STAT

JANUARY 8, 2024

You’re reading the web version of Health Care Inc.,  STAT’s weekly newsletter  following the flow of money in medicine.  Sign up  to get it in your inbox every Monday.  JPM24 is ~here~ The J.P. Morgan Healthcare Conference is exhausting and wildly expensive — a rather apt metaphor for the health care system itself.

Hospitals 285

Hospitals 285

The Pharmacist

JANUARY 8, 2024

Contractors, employed and locum pharmacists are being asked whether they feel ready to launch Pharmacy First at the end of this month. Community Pharmacy England (CPE) has released a survey asking contractors about their opinions about the service. Meanwhile the Pharmacists’ Defence Association has also released its own survey assessing the feelings of employed and […] The post Sector surveyed on Pharmacy First readiness appeared first on The Pharmacist.

Community Pharmacies 95

Community Pharmacies 95

STAT

JANUARY 8, 2024

A group of academic hospitals and technology companies will form a new nonprofit venture to oversee a nationwide network of laboratories to test artificial intelligence tools designed for use in health care. The nonprofit will establish the laboratories at Mayo Clinic, Duke, Stanford, and other major universities and institutions around the country.

Mayo Clinic 282

Mayo Clinic Hospitals 282

The Pharmacist

JANUARY 8, 2024

Staff at a medical warehouse which works with major community pharmacy suppliers have today begun industrial action over trade union recognition issues. Members of the union Unite at Movianto in Bedford, which offers temperature-controlled warehousing to pharmaceutical supply chains including Alliance Healthcare UK and Phoenix, are staging a walkout which is set to last until […] The post Medicines warehouse workers strike over union recognition appeared first on The Pharmacist.

Community Pharmacies 107

Community Pharmacies 107

STAT

JANUARY 8, 2024

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion. It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year.

278

278

Drug Patent Watch

JANUARY 8, 2024

The article “Settled: Patent characteristics and litigation outcomes in the pharmaceutical industry,” explores the relationship between Paragraph IV litigation characteristics and the probability of a Paragraph IV settlement in the… The post Unveiling the Secrets of Patent Litigation and Settlements in Pharmaceuticals appeared first on DrugPatentWatch - Make Better Decisions.

111

111

STAT

JANUARY 8, 2024

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history. He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.

Medicine Expiration 271

Medicine Expiration Biosimilars 271

pharmaphorum

JANUARY 8, 2024

Stay up to date with the latest developments in clinical trials, including updates on Vicore, Mundipharma, Agios, Ultragenyx, EG 427, Orion, and MSD. Find out what these companies are working on and their potential impact on healthcare.

109

109

STAT

JANUARY 8, 2024

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.   The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference , extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Drug Development 270

Drug Development Chemotherapy 270

BioPharma Dive

JANUARY 8, 2024

The chip maker struck a new deal with Amgen on Monday, while Sarepta brought news of strong sales to the J.P. Morgan Healthcare Conference.

122

122

STAT

JANUARY 8, 2024

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week. The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug.

Immunity 246

Immunity Immunization 246

PharmExec

JANUARY 8, 2024

In an interview with Pharmaceutical Executive associate editor Don Tracy, Ashley Gaines, VP, head of breast cancer franchise, discusses newly approved Truqap.

111

111

STAT

JANUARY 8, 2024

Few medications have captured the national attention like Wegovy — and for good reason. In a country with a well-documented obesity epidemic, Wegovy and other members of a new type of weight-loss drug are highly effective: In clinical trials, people on Wegovy typically lose 15% of body weight , and a similar medication, retatrutide, has shown up to 24% weight loss.

Documentation 246

Documentation 246

pharmaphorum

JANUARY 8, 2024

This 12 Questions With Marcus West explores the 60 Seconds remote coaching app founder's journey into corporate coaching and how West realised his clients would improve faster if they dedicated themselves to ongoing microlearning in between coaching sessions.

102

102

STAT

JANUARY 8, 2024

Between Walgreens’ earnings call last week and its J.P. Morgan Healthcare Conference presentation on Monday, it’s becoming clear that the company won’t be acquiring anything anytime soon. “We are not cash rich right now. We’re not in a position where we can do large acquisitions, and I believe we’re not in a position where we need to [in order] to grow the company in a meaningfully responsible way on an earnings basis for the longer term,” said Ti

244

244

BioPharma Dive

JANUARY 8, 2024

At the J.P. Morgan Healthcare Conference Monday, company head Chris Viehbacher said insurance reimbursement is now ‘not an issue’ for treatment.

108

108

STAT

JANUARY 8, 2024

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead. The deal includes up to another $400 million in payments if certain milestones are met. Aiolos was launched just last year , based in both San Francisco and London.

Drug Development 243

Drug Development 243

pharmaphorum

JANUARY 8, 2024

Alphabet’s AI in drug discovery startup Isomorphic Labs signs collaborations with Eli Lilly and Novartis worth up to $3bn, its first two pharma partnerships

104

104

STAT

JANUARY 8, 2024

Cure Ventures , a Boston-based venture capital firm founded in 2021 by a trio of veteran biotech investors, has brought in two former executives from Sage Therapeutics to prepare them for investing in neuroscience startups. The VC firm has hired Jeff Jonas, Sage’s former chief executive, and Al Robichaud, Sage’s former chief scientific officer, as partners, the team told STAT exclusively.

Labelling 229

Labelling 229

pharmaphorum

JANUARY 8, 2024

JPM24 starts with three takeovers including J&J's $2bn bid for Ambrx, Merck’s $680m play for Harpoon Therapeutics and a $425m offer from Novartis for Calypso Biotech

96

96

STAT

JANUARY 8, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because the familiar routine of online meetings and deadlines has returned. Moreover, today marks the start of the annual J.P. Morgan Healthcare Conference — the Woodstock-like gathering of biopharma execs and dealmakers — which always suggests, if not delivers, a bevy of activity.

Pharmaceutical Companies 205

Pharmaceutical Companies Pharmaceutical Companies 205

Express Pharma

JANUARY 8, 2024

Lupin Life, the consumer healthcare business of Lupin announced the second edition of the Aptivate Champion Run for Kids scheduled on January 14, 2024, at MMRDA Grounds, Bandra Kurla Complex, Mumbai. The Aptivate Champion Run aims to raise awareness about children’s health and wellbeing through physical activity and promoting healthy eating habits. This edition of Aptivate Champion Run participants offers three distinct categories: a 500-meter run for children aged 4–7 years (accompanied by pare

Immunity 98

Immunity Immunization 98

STAT

JANUARY 8, 2024

In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San Francisco conference, join our newsletter list. “The lanyards” have landed! Apparently, that’s what the good folks of San Francisco call everyone who descends on the city for the J.P Morgan Healthcare Conference.

Drug Pricing 190

Drug Pricing Drug Development 190

European Pharmaceutical Review

JANUARY 8, 2024

RYSTIGGO ® (rozanolixizumab) is the first therapy approved in Europe for adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive generalised myasthenia gravis (gMG). The European Commission (EC) has now granted a marketing authorisation for biopharma company UCB’s treatment, as an add-on to standard therapy in patients who have this rare autoimmune condition.

Adverse Reactions 94

Adverse Reactions 94